sponsored content

A CLINICAL TRIAL IN COLORECTAL CANCER EVALUATES THE IMPACT OF HIFAS DA TERRA’S NATURAL IMMUNOMODULATOR MICO-DIGEST 2.0

Hifas da Terra (HdT) ...

Hifas da Terra and the Fundación Biomédica Galicia Sur are collaborating on a clinical trial using Mico-Digest 2.0, a natural mushroom formula developed by HdT, which works as a natural immunomodulator. The trial is studying one of HdT’s most innovative products, which contains medicinal mushroom extracts with a high concentration of natural bioactive compounds. The study is registered in the international portal clinicaltrials.gov, and will evaluate the impact of Mico-Digest 2.0 supplementation in relation to the rate of postoperative complications, modification of the microbiota, the reduction of inflammatory parameters and digestive wellbeing; aspects related to the immune response of patients.

In the summer of 2021, the Pontevedra-Vigo-Ourense Research Ethics Committee, promoted by the Fundación Biomédica Galicia Sur, authorised this clinical trial, which, for the first time, includes a nutraceutical from Hifas da Terra made from a synergistic combination of several medicinal mushroom extracts, with the objective of reducing the risk of postoperative complications in patients with colorectal cancer undergoing surgery.

Fungal polysaccharides have attracted attention for their role in modulating the gut microbiota. It appears that this type of polysaccharide could reduce pathogen levels and stimulate the growth of beneficial microorganisms. Their anti-inflammatory activity has also been observed. Research has also demonstrated that the combination of a range of different fungal extracts sends multiple stimuli to the immune system by increasing intracellular reactions and interactions. Therefore, the synergistic mushroom extract nutraceutical MICODIGEST 2.0 could be used to reduce complications after colorectal cancer surgery.

The study titled, “Randomised double-blind clinical trial to evaluate the effect of preoperative administration of the nutraceutical MICODIGEST 2.0 on complications associated with surgery for colorectal cancer treated with curative intent,” is a pioneering trial in the field of oncology. This clinical study will evaluate how the prebiotic and anti-inflammatory effects of Mico-Digest 2.0 from Hifas da Terra can reduce postoperative complications that affect 20% of patients undergoing surgery.

According to the R&D department of Hifas da Terra, these complications are also a risk factor for the recurrence of the disease in different types of neoplasms. “We know that the bacteria present in the microbiota could play an important role in the prevention of colorectal cancer. In this study, we will look at the inflammatory impact of modifying the microbiota,” they say. “We hope that the application of the nutraceutical Mico-Digest 2.0, due to its anti-inflammatory and microbiota modulating effects, will have a positive effect on the patient’s immune response,” they add.

Read More